Shift Bioscience
Shift Bioscience is a biotechnology company developing cell rejuvenation therapies to reverse age-driven diseases by targeting the aging cell. The company has built a best-in-class target discovery platform combining a novel aging clock (AC4) and virtual cell model to remove the primary bottleneck for discovery of cellular aging and rejuvenation targets, enabling identification of hundreds of novel targets linked to…
Funding snapshot
About
Shift Bioscience is a biotechnology company developing cell rejuvenation therapies to reverse age-driven diseases by targeting the aging cell. The company has built a best-in-class target discovery platform combining a novel aging clock (AC4) and virtual cell model to remove the primary bottleneck for discovery of cellular aging and rejuvenation targets, enabling identification of hundreds of novel targets linked to disease states. Its lead product, SB101, is an anti-fibrotic siRNA therapeutic that reverses epigenetic aging clocks in multiple cell types through a genetically validated fibrosis pathway, with first-in-class opportunities in liver fibrosis and expansion potential to secondary fibrosis in lung and heart. The company has published research on AI virtual cells for genetic perturbation modeling and holds a comprehensive IP package with patent life extending to 2046. Founded in 2017 and headquartered in Cambridge, UK, with computational operations in Toronto, Canada, Shift Bioscience has raised approximately $28.6M in seed funding from investors including BGF, F-Prime Capital, Kindred Capital, and Healthspan Capital.
Business model
Gastroenterology > Drugs > Liver Diseases,
ENT Disorders > Drugs,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics > Cellular Rejuvenation
Team background
College Wise > University of Cambridge
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.